Rhenman & Partners Asset Management AB increased its position in shares of Xencor Inc (NASDAQ:XNCR) by 49.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 325,965 shares of the biopharmaceutical company’s stock after acquiring an additional 107,428 shares during the period. Rhenman & Partners Asset Management AB owned about 0.58% of Xencor worth $10,124,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in shares of Xencor by 5.2% during the third quarter. JPMorgan Chase & Co. now owns 251,155 shares of the biopharmaceutical company’s stock worth $9,787,000 after acquiring an additional 12,320 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of Xencor during the third quarter worth $142,000. Tekla Capital Management LLC purchased a new stake in shares of Xencor during the fourth quarter worth $2,031,000. AQR Capital Management LLC raised its holdings in shares of Xencor by 105.6% during the third quarter. AQR Capital Management LLC now owns 63,061 shares of the biopharmaceutical company’s stock worth $2,457,000 after acquiring an additional 32,389 shares in the last quarter. Finally, 361 Capital LLC purchased a new stake in shares of Xencor during the fourth quarter worth $2,596,000. Institutional investors and hedge funds own 84.71% of the company’s stock.
NASDAQ XNCR opened at $31.62 on Thursday. Xencor Inc has a fifty-two week low of $27.57 and a fifty-two week high of $48.38. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -24.14 and a beta of 1.40.
Several analysts recently issued reports on XNCR shares. Raymond James initiated coverage on Xencor in a report on Thursday, March 14th. They set an “outperform” rating and a $27.85 price objective for the company. BidaskClub upgraded Xencor from a “hold” rating to a “buy” rating in a report on Tuesday, January 1st. Piper Jaffray Companies raised their target price on Xencor to $56.00 and gave the company an “overweight” rating in a report on Tuesday, February 26th. Cantor Fitzgerald restated a “buy” rating and set a $40.00 target price on shares of Xencor in a report on Tuesday, February 5th. Finally, ValuEngine lowered Xencor from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. Two research analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $41.43.
In related news, major shareholder John S. Stafford III bought 2,000 shares of the business’s stock in a transaction on Friday, March 22nd. The shares were bought at an average cost of $29.96 per share, for a total transaction of $59,920.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III bought 1,100 shares of the business’s stock in a transaction on Monday, March 18th. The shares were bought at an average price of $29.90 per share, for a total transaction of $32,890.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 46,900 shares of company stock worth $1,368,396. Corporate insiders own 4.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Fairfield Current and is owned by of Fairfield Current. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.fairfieldcurrent.com/news/2019/04/11/rhenman-partners-asset-management-ab-purchases-107428-shares-of-xencor-inc-xncr.html.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Featured Article: What is a Lock-Up Period?
Want to see what other hedge funds are holding XNCR?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).
Receive News & Ratings for Xencor Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Xencor and related companies with MarketBeat.com’s FREE daily email newsletter.